Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 400 of 885 entries
View as:

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02472145 Org: User:
Start: 08/04/15 End: 01/25/18 Due: 01/25/19

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT00487539 Org: User:
Start: 08/31/07 End: 10/31/10 Due: 10/31/11

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

Phase: N/A Priority: Normal
NCT ID: NCT02039245 Org: User:
Start: 01/31/14 End: 03/31/14 Due: 03/31/15

A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02343289 Org: User:
Start: 01/31/15 End: 04/30/15 Due: 04/30/16

Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

Phase: N/A Priority: Normal
NCT ID: NCT02243202 Org: User:
Start: 09/30/14 End: 06/30/15 Due: 06/30/16

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Phase: N/A Priority: Normal
NCT ID: NCT02111564 Org: User:
Start: 01/07/14 End: 05/03/18 Due: 05/03/19

A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT01902550 Org: User:
Start: 07/31/13 End: 05/31/14 Due: 05/31/15

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06532032 Org: User:
Start: 07/23/24 End: 10/21/25 Due: 10/21/26

A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01853228 Org: User:
Start: 10/22/13 End: 08/28/17 Due: 08/28/18

A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01643889 Org: User:
Start: 07/31/12 End: 11/30/12 Due: 11/30/13

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Phase: N/A Priority: Normal
NCT ID: NCT04264806 Org: User:
Start: 05/06/21 End: 01/28/25 Due: 01/28/26

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT01959282 Org: User:
Start: 11/15/13 End: 12/05/15 Due: 12/05/16

A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.

Phase: N/A Priority: Normal
NCT ID: NCT01970020 Org: User:
Start: 10/31/12 End: 12/31/12 Due: 12/31/13

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Phase: N/A Priority: Normal
NCT ID: NCT05161598 Org: User:
Start: - End: - Due: -

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Phase: N/A Priority: Normal
NCT ID: NCT01985126 Org: User:
Start: 09/27/13 End: 05/30/17 Due: 05/30/18

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01381874 Org: User:
Start: 08/24/11 End: 08/08/18 Due: 08/08/19

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT03301207 Org: User:
Start: 10/20/17 End: 12/04/18 Due: 12/04/19

Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02477891 Org: User:
Start: - End: - Due: -

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Phase: N/A Priority: Normal
NCT ID: NCT00747526 Org: User:
Start: 12/31/07 End: 02/29/12 Due: 02/28/13

A Study of Golimumab in Participants With Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02181673 Org: User:
Start: 09/08/14 End: 03/22/17 Due: 03/22/18

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

Phase: N/A Priority: Normal
NCT ID: NCT01366664 Org: User:
Start: 04/30/11 End: 04/30/12 Due: 04/30/13

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Phase: N/A Priority: Normal
NCT ID: NCT02139943 Org: User:
Start: 05/31/14 End: 06/30/15 Due: 06/30/16

A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)

Phase: N/A Priority: Normal
NCT ID: NCT01090427 Org: User:
Start: 05/31/10 End: 01/31/14 Due: 01/31/15

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Phase: N/A Priority: Normal
NCT ID: NCT04113551 Org: User:
Start: 10/01/19 End: 01/10/20 Due: 01/10/21

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02949206 Org: User:
Start: 11/14/16 End: 08/09/17 Due: 08/09/18